Recent Advances in Handheld and Robotic Bioprinting Approach for Tissue Engineering
Kamaraj M., Moghimi N., Joshi A., Rezayof O., Barer A., Cao S.
Laboratory Study, published in Adv Mater Technol (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Adv Mater Technol (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40896112
- PMCID
- PMC12396635
- DOI
- 10.1002/admt.202500206
- Citations
- 1
Abstract (original English)
3D bioprinting has emerged as a transformative technology in tissue engineering, significantly impacting the creation of patient-specific tissues to enhance clinical outcomes. Despite its rapid advancement, translating this technology from bench to bedside remains a critical clinical need. New bioprinting approaches, such as handheld printers or robotic arm-driven in-situ biofabrication techniques, have emerged as promising alternatives. These advancements enable the reconstruction of damaged tissue directly on living anatomical structures, offering adaptability and precise matching to the affected area. The integration of biomaterials, tissue engineering principles, and digital technologies, particularly robotics, has garnered substantial interest from both academic and industrial sectors, highlighting its potential for clinical applications. However, challenges persist, including refining bioink formulations, adjusting mechanical properties, facilitating in situ crosslinking, and accurately mimicking the extracellular matrix. This review explores the cutting-edge frontier of in situ 3D bioprinting for tissue regeneration, utilizing both handheld and robotic arm-assisted 3D printers. It systematically examines the relative advantages, disadvantages, challenges, and prospects of this technology as it transitions from bench side to bed side.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.